Flexion Therapeutics (NASDAQ:FLXN) announces preliminary Q2 ZILRETTA net sales of $15.4M, vs. Q2 total sales consensus of $9.97M.
Demand for ZILRETTA increased month-over-month throughout Q2 with purchases by healthcare providers reaching 4,863 units, 13,547 units and 18,287 units in April, May and June, respectively, with total demand in line with Q1.
In addition, the Company also plans to recommence ZILRETTA manufacturing in Q4.
Flexion expects to report its complete Q2 results in August.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.